Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human therapeutic antibodies.

C A Borrebaeck1, R Carlsson

  • 1Department of Immunotechnology, Lund University, Sweden. carl.borrebaeck@immun.lth.se

Current Opinion in Pharmacology
|November 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection and characterization of a lectin from non-seed tissue ofPhaseolus vulgaris.

Planta·2013
Same author

Letter: coeliac disease and ischaemic heart disease--a true additional risk factor? Authors' reply.

Alimentary pharmacology & therapeutics·2013
Same author

The characterisation and risk factors of ischaemic heart disease in patients with coeliac disease.

Alimentary pharmacology & therapeutics·2013
Same author

Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis.

Acta psychiatrica Scandinavica·2006
Same author

Patients with ischemic heart disease: quality of life predicts long-term mortality.

Scandinavian cardiovascular journal : SCJ·2005
Same author

Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study.

Scandinavian journal of gastroenterology·2005

Generating high-affinity human antibodies is now feasible. The main challenge lies in selecting effective cancer therapy targets that signal into cells, offering hope for future antibody treatments.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Genetic engineering advances enable high-affinity human antibody generation.
  • Antibody-based therapies show promise in treating autoimmune diseases and cancers.
  • Identifying effective therapeutic targets remains a critical challenge.

Purpose of the Study:

  • To highlight the shift in focus from antibody generation to target selection in therapeutic development.
  • To discuss the importance of intracellular signaling in target molecule selection for antibody therapy.
  • To review recent advancements and future prospects of antibody-based therapeutics.

Main Methods:

  • Review of current literature on antibody engineering and therapeutic applications.
  • Analysis of clinical successes of antibody therapies like rituximab (anti-CD20) and anti-tumor necrosis factor-alpha.

Related Experiment Videos

  • Discussion of emerging strategies for identifying and validating novel therapeutic targets.

    • Main Results:

    • High-affinity human antibody generation is no longer a primary limitation.
    • Intracellularly signaling target molecules are increasingly preferred for therapeutic intervention.
    • Clinical data supports the efficacy of antibody therapies in non-Hodgkin's lymphoma and Crohn's disease.

    Conclusions:

    • The future of antibody-based therapy is promising, driven by technological progress and a deeper understanding of mechanisms of action.
    • Effective target selection is paramount for successful antibody-based cancer therapy.
    • Continued research into novel antibody designs and target identification will expand therapeutic options.